Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | International Journal of Oncology |
| Citation | |
| Doi | http://dx.doi.org/10.3892/ijo.2012.1576 |
| Field | Oncology and hematology |
| Keywords | breast cancer; HER2 protein; trastuzumab; AKT1 protein; AKT2 protein; prognosis |
| Description | Trastuzumab is effective in about half of HER2- positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular localization of selected Akt isoforms and response to trastuzumab-based anti-HER2 targeted therapy in patients with HER2-positive metastatic breast cancer. |